日本与白人患者迟发性急性及NIH慢性GVHD特征与结局比较
本研究比较了413例日本与708例白人患者首次异基因造血干细胞移植后迟发性急性GVHD和NIH慢性GVHD的发生率、部位、严重程度及结局。日本患者迟发性急性GVHD发生率相似但肝脏受累更常见、胃肠道受累更少,且更易停用系统免疫抑制;慢性GVHD发生率更低,口腔、眼和肝脏受累更常见,胃肠道受累更少。
要点
- 日本患者迟发性急性GVHD肝脏受累(转氨酶升高)比例显著高于白人,胃肠道受累比例更低。
- 日本患者迟发性急性GVHD后停用系统免疫抑制的可能性更高(HR 3.68)。
- 日本患者NIH慢性GVHD发生率更低,但口腔、眼和肝脏受累更常见,胃肠道受累更少。
核心结论
- 日本与白人患者迟发性急性GVHD和NIH慢性GVHD的发生率、受累部位、严重程度及临床结局存在差异。
研究设计与样本
- 回顾性比较研究,纳入首次异基因造血干细胞移植后日本患者413例与白人患者708例。
- 分析按骨髓移植(BMT)或外周血干细胞移植(PBSCT)分层。
主要发现
- 迟发性急性GVHD发生率:BMT日本19% vs 白人16%;PBSCT日本19% vs 白人16%。
- 肝脏迟发性急性GVHD(转氨酶升高定义):BMT日本79% vs 白人8%;PBSCT日本92% vs 白人33%。
- 胃肠道迟发性急性GVHD:BMT日本11% vs 白人58%;PBSCT日本20% vs 白人68%。
- 迟发性急性GVHD后停用系统免疫抑制:日本 vs 白人HR 3.68(95%CI 1.96-6.94,P < .001)。
- NIH慢性GVHD发生率:BMT日本15% vs 白人30%(P = .002);PBSCT日本37% vs 白人45%(P < .001)。
关键数值与推荐
- 日本患者慢性GVHD口腔、眼和肝脏受累更频繁,胃肠道慢性GVHD更少。
- NIH慢性GVHD免疫抑制治疗持续时间两种族相似。
临床怎么用
- 临床评估GVHD时应考虑种族差异对受累部位和严重程度的影响。
局限性
- 差异不能完全归因于中心间实践变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although differences in the incidence of chronic graft-versus-host disease (GVHD) across the races have been suggested, these have not been systematically investigated. This study compared the incidence, sites, severity, and outcomes of late acute GVHD and chronic GVHD according to National Institutes of Health (NIH) consensus criteria between Japanese (n = 413) and white (n = 708) patients after first allogeneic hematopoietic cell transplantation. Analysis was stratified according to bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT). Japanese patients, compared with white patients, had a similar incidence of late acute GVHD (BMT, 19% vs 16%; PBSCT, 19% vs 16%) but experienced more frequent liver late acute GVHD as defined by transaminase elevation (BMT, 79% vs 8%; PBSCT, 92% vs 33%) and less frequent gastrointestinal late acute GVHD (BMT, 11% vs 58%; PBSCT, 20% vs 68%). Japanese patients were more likely to discontinue systemic immunosuppression after late acute GVHD than white patients (hazard ratio, 3.68; 95% confidence interval, 1.96-6.94; P < .001). Japanese patients, compared with white patients, had a lower incidence of chronic GVHD (BMT, 15% vs 30% [P = .002]; PBSCT, 37% vs 45% [P < .001]) and experienced more frequent chronic GVHD of the mouth, eyes, and liver and less frequent gastrointestinal chronic GVHD. The duration of immunosuppressive treatment of NIH chronic GVHD was similar between the races. These differences could not be entirely attributed to practice variation between the centers. This study shows that the incidence, affected sites, severity, and clinical outcomes of late acute GVHD and NIH chronic GVHD differ between Japanese and white patients.
引用
- Inamoto Y, White J, Ito R, et al. Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Adv. 2019. PMID: 31551243. doi:10.1182/bloodadvances.2019000386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。